Thursday, June 29, 2023
Avanos Medical has expressed its support for the recent announcement by the UK's National Institute for Health and Care Excellence (NICE) recommending the use of radiofrequency ablation (RFA) for treating osteoarthritic knee pain. According to NICE, RFA involves the use of radiofrequency energy to denervate target nerves, with options including conventional radiofrequency, cooled radiofrequency, or pulsed radiofrequency. The procedure aims to reduce pain and delay the need for knee arthroplasty. NICE has found good evidence showing that RFA effectively relieves pain in the short term, and there are no significant safety concerns or major complications, except for recognized numbness.
Dieter Krines, Avanos Vice President & General Manager, Europe, expressed great satisfaction with NICE's recommendation and looks forward to collaborating with healthcare providers to make RFA treatment available to eligible patients across the UK.
Osteoarthritis is the most prevalent form of arthritis, and Avanos' RFA pain management products provide a minimally invasive solution for patients who are not yet ready for surgery, offering relief without the use of opioids.
Dr. Robin Correa, Consultant Pain Management and Anaesthetics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, welcomed NICE's recommendation for RFA therapy in treating osteoarthritic knee pain. Dr. Correa has personally witnessed the positive impact of this treatment on patients' quality of life and hopes that the publication of NICE's recommendations will raise awareness about this innovative therapy, ultimately leading to improved outcomes for a larger number of patients.